Another recent multicenter randomized trial discovered that 68Ga PSMA PET-CT had a 92% accuracy rate and was superior to bone scan and CT in males with high-risk prostate cancer (Gleason grading group 3-5, PSA 20, or clinical stage T3). The gene discussed is FOLH1; the disease is prostate cancer.